Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11070
Title: The use of PET in assessing tumor response after neoadjuvant chemoradiation for rectal cancer.
Authors: Mak, Daisy;Joon, Daryl Lim;Chao, Michael;Wada, Morikatsu;Joon, Michael Lim;See, Andrew;Feigen, Malcolm;Jenkins, Patricia;Mercuri, Angelina;McNamara, Joanne;Poon, Aurora M T;Khoo, Vincent
Affiliation: Radiation Oncology Centre, Austin Health, Heidelberg West, Australia.
Issue Date: 1-Jul-2010
Citation: Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology 2010; 97(2): 205-11
Abstract: To assess the correlation of 18F-FDG-PET (PET) response to pathological response after neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer.Twenty patients with locally advanced rectal cancer were identified between 2001 and 2005. The median age was 57 years (range 37-72) with 14 males and 6 females. All patients were staged with endorectal ultrasound and/or MRI, CT, and PET. The clinical staging was T3N0M0 (16), T3N1M0 (2), and T3N0M1 (2). Restaging PET was performed after CRT, and prior to definitive surgery. The response on PET and pathology was assessed and correlated. Patient outcome according to PET response was also assessed.Following CRT, a complete PET response occurred in 7 patients, incomplete response in 10, and no response in 3 patients. At surgery, complete pathological response was recorded in 7 patients, incomplete response in 10 and no response in 3. There was a good correlation of PET and pathological responses in complete responders (5/7 cases) and non-responders (3/3 cases). After a median follow-up of 62 months (range 7-73), twelve patients were alive with no evidence of disease. All patients achieving complete metabolic response were alive with no evidence of disease, while as those who had no metabolic response, all died as a result of metastatic disease.PET is a promising complementary assessment tool for assessing tumor response after CRT if there is a complete or no response. PET response may also predict for outcome.
Internal ID Number: 20598390
URI: http://ahro.austin.org.au/austinjspui/handle/1/11070
DOI: 10.1016/j.radonc.2010.05.016
URL: http://www.ncbi.nlm.nih.gov/pubmed/20598390
Type: Journal Article
Subjects: Adult
Aged
Female
Fluorodeoxyglucose F18.diagnostic use
Follow-Up Studies
Humans
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Positron-Emission Tomography
Rectal Neoplasms.diagnosis.pathology.therapy
Retrospective Studies
Treatment Outcome
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.